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With a lifetime incidence of up to 12% in man and 6% in
woman, nephrolithiasis is a major health problem worldwide.
Approximately, 80% of kidney stones are composed of
calcium and hypercalciuria is found in up to 40% of
stone-formers. Although the mechanisms resulting in
precipitation and growth of calcium crystals in the urinary
tract are multiple and not fully understood, hypercalciuria
per se is recognized as an important and reversible risk
factor in stone formation. In this brief review, we summarize
the studies assessing the heritability of hypercalciuria and
pinpoint recently identified human genetic disorders as well
as relevant animal models that provided new insights into
the segment-specific tubular handling of calcium and the
pathophysiology of renal hypercalciuria and kidney stones.
We also discuss novel strategies that may help to unravel the
genetic bases of such complex conditions.
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With a lifetime incidence of up to 12% in man and 6% in
woman, a constant increase in industrialized countries and a
recurrence rate close to 10% per annum, nephrolithiasis is a
major health problem worldwide. Lifestyle factors, essentially
dietary habits, play an important role in kidney stone
formation, as recently reviewed in the Journal.1 About 80%
of kidney stones are composed of calcium (either oxalate or
phosphate) and hypercalciuria is found in up to 40% of
stone-formers.2 Although the mechanisms resulting in
precipitation and growth of calcium crystals in the urinary
tract are multiple and not fully understood, hypercalciuria
per se is recognized as an important and reversible risk factor
in stone formation. Calcium homeostasis reflects the balance
between absorption in the intestine, excretion by the kidney,
and exchange from bone, the three processes being tightly
regulated by endocrine mechanisms. Accordingly, the patho-
physiology of hypercalciuria has been classified into (i)
primary renal leak; (ii) imbalance between bone resorption
and formation; and (iii) gut hyperabsorption. In turn, these
primary defects trigger compensatory mechanisms primarily
mediated by parathyroid hormone (PTH) and 1,25-dihy-
droxy-vitamin D3 (1,25(OH)2D3).
3
A genetic control of hypercalciuria has been suspected for
long, based on epidemiological studies which demonstrated
that about half of patients with idiopathic hypercalciuria had
a family history of nephrolithiasis, with more frequent stone
disease in first-degree relatives (for review, Coe et al.2 and
Moe and Bonny3). This genetic influence is balanced by the
risk profile due to environmental and/or dietary factors:
familial aggregation is less prevalent in countries with a high-
risk lifestyle (e.g. the United States) than in areas with a
protective diet (Mediterranean countries). However, the
influence of genetic factors appears to be far greater than
diet-related risks.4 Hypercalciuria is a quantitative trait that
cannot be dissected with a single Mendelian approach.
Interpretation of hypercalciuria with respect to disease
must integrate a series of clinical parameters (such as
urine volume or pH, and the excretion of lithogenic vs
protective factors), the fact that it may be either the primary
event or a compensatory manifestation, and the potential
influence of modifier genes involved in multiple pathways
(vitamin D pathway; oxalate metabolism; promoters or
inhibitors of urine crystallization; bone and intestine calcium
handling).3
One way to face the complexity of hypercalciuria as a
risk factor is to consider the insights gained from the
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identification of rare, monogenic diseases associated with hy-
percalciuria and/or kidney stones in man, and the investiga-
tions of animal models. In this brief review, we will summarize
the studies assessing the heritability of hypercalciuria, and will
discuss recently identified human genetic disorders and animal
models relevant for kidney stones and hypercalciuria of renal
origin. We will end in considering promising approaches to
unravel the genetic bases of this condition.
HERITABILITY OF CALCIURIA
The heritability of urine calcium excretion, that is the
proportion of its variation attributable to genetic factors, has
been established by a series of family-based studies. The
classical twin study is based on the fact that monozygotic
(MZ) twins share identical genotypes, whereas dizygotic
(DZ) twins share on average 50% of their segregating genes.
If MZ twins show a greater resemblance for a specific trait
than DZ twins, this is likely to be due to genetic factors. In
such a study, performed in 1747 adult female twin pairs (539
MZ and 1208 DZ pairs) from the St Thomas’ UK Adult Twin
Registry, the intraclass correlation for urinary calcium
excretion was higher in MZ twin pairs, and heritability for
this parameter was 52%.5 Using the same approach in 3391
twin pairs (1928 MZ and 1463 DZ pairs) from the VET
Registry, Goldfarb et al.6 showed that the proband con-
cordance rate of kidney stones was significantly greater in MZ
twins than DZ twins (32.4 vs 17.3%, Po0.001), and the
heritability of the risk of stones was 56%.
The Bonnardeaux group in Montreal studied the segrega-
tion of hypercalciuria in 567 individuals from 221 French-
Canadian nuclear families extracted from 154 pedigrees,
some of which were four generations, with at least two
siblings having a history of calcium stones.7 They developed a
computer program comparing the likelihood of three models
of inheritance of calciuria: a single major gene (dominant,
recessive, or codominant); several genes, each with a small
effect; and a mixed major gene/polygenic model. The best
results were obtained with the single-gene co-dominant and
the mixed co-dominant/polygenic models: in both, the
heritability attributable to the major gene was estimated to
be 58%. Taken together, these studies suggest that more than
50% of the urinary calcium excretion rate is genetically
determined and that a major gene may account for it, at least
in some stone-formers families.
MONOGENIC DISORDERS LEADING TO HYPERCALCIURIA AND
NEPHROLITHIASIS
Dent’s disease
Dent’s disease belongs to a group of X-linked disorders that
are primarily associated with inactivating mutations in the
CLCN5 gene (Table 1).8 Dent’s disease is characterized by
proximal tubule (PT) dysfunction and low-molecular-weight
proteinuria, associated with hypercalciuria, nephrolithiasis,
nephrocalcinosis, and progressive renal failure. Hypercalciuria
and nephrocalcinosis are highly prevalent (95 and 75% of
patients, respectively), but there is considerable inter- and
intra-familial variability in the occurrence of nephrolithiasis
(approximately half of the patients). Progression to end-stage
renal failure occurs between the third and the fifth decades of
life in 30–80% of affected males.9 CLCN5 is a member of the
CLC gene family of chloride channels and transporters that
have been identified by the laboratory of T Jentsch (ref 10 for
review). CLCN5 encodes ClC-5, an isoform that is pre-
dominantly expressed in the kidney, where it is located in the
PT, the thick ascending limb (TAL) of Henle’s loop, and the
a-type intercalated cells of the collecting ducts (CD).10,11
Around 100 families harboring CLCN5 mutations have been
identified thus far. These mutations abolish the currents
induced by ClC-5 in heterologous expression systems.8 Of
note, mutations in the OCRL1 gene encoding a phosphati-
dylinositol bisphosphate 5-phosphatase have recently been
identified in a subset of patients with Dent’s disease negative
for CLCN5 mutations.12 Mutations in OCRL1 have been
previously associated with the oculo-cerebro-renal syndrome
of Lowe (OCRL), an X-linked disorder characterized by
bilateral congenital cataract, severe mental retardation, renal
Fanconi syndrome, and, in some patients, hypercalciuria and
nephrolithiasis (Table 1).
Studies in two strains of ClC-5-knockout (KO) mice
provided insights into the link between PT dysfunction and
hypercalciuria and nephrolithiasis in Dent’s disease13,14
(Figure 1). In PT cells, ClC-5 co-distributes with the vacuolar
Hþ -ATPase in the early endosomes, which are responsible
for the reabsorption and processing of albumin and low-
molecular-weight proteins that are filtered by the glomerulus.
These vesicles belong to the receptor-mediated endocytic
pathway, which involves the multiligand tandem receptors,
megalin and cubilin, located at the apical brush border of PT
cells.15 Progression along the endocytic pathway depends on
endosomal acidification, driven by the vacuolar Hþ -ATPase
and requiring a parallel chloride conductance for electro-
neutrality. Accordingly, the defect in PT endocytosis observed
in Dent’s disease patients and mice lacking ClC-5 is
attributed to a reduced acidification, at least in some
endosomes, secondary to the loss of the chloride permeability
mediated by ClC-5.16 The inactivation of ClC-5 is also
associated with a severe trafficking defect in PT cells, with
loss of megalin and cubilin at the brush border, subsequent
loss of their ligands in the urine, and impaired lysosomal
processing.13,14,17 As the megalin/cubilin complex mediates
the reabsorption of the vitamin-D-binding protein (DBP)
and PTH that are filtered by the glomerulus,15 the urinary
loss of these mediators could potentially lead to opposite
effects in PT cells, resulting in variable levels of active
1,25(OH)2D3 levels in the serum.
16 Such variability could
explain why renal hypercalciuria and kidney stones are
present in one strain of ClC-5 KO mouse14 but not in the
other,13 reflecting the phenotype variability observed in
patients.9 The potential role(s) of ClC-5 in the TAL
(regulated calcium reabsorption) and in the intercalated cells
(distal urinary acidification) remain(s) to be defined.11 Of
interest, no CLCN5 mutations have been detected in patients
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with idiopathic hypercalciuria4 and in the genetic hypercal-
ciuric stone-forming (GHS) rat strain (see below).
Hereditary hypophosphatemic rickets with hypercalciuria
Hereditary hypophosphatemic rickets with hypercalciuria
(HHRH) is an autosomal recessive disorder characterized by
renal phosphate wasting, with hypophosphatemia and
rickets, resulting in a compensatory increase in
1,25(OH)2D3 levels favoring intestinal absorption of phos-
phate and calcium, and hypercalciuria. The combination of
hypercalciuria and phosphaturia, similar to Dent’s disease, is
associated with nephrocalcinosis and kidney stones.18 The
Table 1 | Monogenic human disorders associated with renal hypercalciuria and nephrolithiasis
Mode of inheritance
disease MIM Gene, protein, function Segment
Pathophysiology, renal
manifestations
Extra-renal
manifestations
X-linked
Dent’s disease (1) (X-linked
recessive nephrolithiasis; X-linked
hypophosphatemic rickets;
idiopathic low-molecular-weight
proteinuria)
300009 CLCN5, ClC-5 Cl/H+
exchanger
PT, TAL, ICa Trafficking defect, defective
endocytosis
PT dysfunction, renal Fanconi
syndrome
Nephrocalcinosis, stones
Impaired urine acidification
Renal failure
Rickets
Lowe’s syndrome (oculo-cerebro-
renal syndrome)
Dent’s disease (2)
309000
300555
OCRL, OCRL1
Phosphatidylinositol 4,5-
bisphosphate-5-
phosphatase
PT PT dysfunction, renal Fanconi
syndrome
Proximal RTA, metabolic acidosis
Nephrocalcinosis, stones
Mental retardation,
cataract, rickets,
cryptorchidism,
neuromuscular and
behavioral
abnormalities, growth
delay
Autosomal dominant
Autosomal dominant
hypocalcemia (ADH) (Bartter-like
syndrome type V)
146200 CASR, CaSR
Calcium-sensing
receptor
PT, TAL, DCT,
CD
Gain-of-function mutations
Low serum PTH
Hypocalcemia, hypercalciuria
Nephrocalcinosis, stones
(vitamin D)
Salt-losing nephropathy,
hypokalemia
Neuromuscular
manifestations of
hypocalcemia, seizures,
basal ganglia
calcifications
Distal renal tubular acidosis
(dRTA, RTA type I)
179800 SLC4A1, AE1
Cl/HCO3
 exchanger
ICa Impaired anion exchange in ICa
Metabolic acidosis, hypercalciuria
Nephrocalcinosis, stones
Osteomalacia, rickets,
growth retardation
Autosomal recessive
Antenatal Bartter’s syndrome
type I (hyperprostaglandin E
syndrome)
601678 SLC12A1, NKCC2
Na+-K+-2Cl
co-transporter 2
TAL Profound salt-wasting, polyuria
Metabolic alkalosis, hypokalemia
Hyperprostaglandinuria
Hypercalciuria, nephrocalcinosis
Polyhydramnios,
prematurity, fever,
vomiting, diarrhea,
osteopenia
Antenatal Bartter’s syndrome
type II (hyperprostaglandin E
syndrome 2)
241200 KCNJ1, ROMK
K+ channel
TAL, CD Profound salt-wasting, polyuria
Transient (neonatal) hyperkalemia
Metabolic alkalosis, hypokalemia
Hyperprostaglandinuria
Hypercalciuria, nephrocalcinosis
Polyhydramnios,
prematurity, Fever,
vomiting, diarrhea,
osteopenia
Bartter’s syndrome type III
(classic Bartter’s syndrome)
607364 CLCNKB, ClC-Kb
Cl channel
TAL, DCT Highly variable phenotype
Variable calciuria levels, stones
Variable
(polyhydramnios)
Familial hypomagnesemia with
hypercalciuria and
nephrocalcinosis (FHHNC)
248250 CLDN16 (PCLN1),
Claudin-16, paracellin-1
Tight junction protein
TAL, DCT Impaired paracellular transport of
calcium and magnesium
Calcium and magnesium wasting,
renal failure, nephrocalcinosis,
stones
Incomplete distal tubular acidosis
Convulsions, tetany,
chondrocalcinosis,
neuromuscular
manifestations
Distal renal tubular acidosis
(dRTA with progressive nerve
deafness)
267300 ATP6V1B1, V1 subunit B1
Subunit of V-ATPase
ICa Impaired urine acidification
Metabolic acidosis, kaliuresis
Hypercalciuria, nephrocalcinosis,
stones
Sensorineural hearing
loss, hypokalemic
paralysis, rickets, growth
impairment
Distal renal tubular acidosis
(dRTA with preserved hearing or
late onset hearing loss)
602722 ATPV0A4, V0 subunit a4
Subunit of V-ATPase
ICa Normal hearing or late
onset sensorineural
hearing loss, paralysis,
rickets, growth
impairment
CD, collecting duct; DCT, distal convoluted tubule; dRTA, distal renal tubular acidosis; ICa, intercalated cell (a-type); RTA, renal tubular acidosis; PT, proximal tubule; TAL, thick
ascending limb of Henle’s loop; V-ATPase, vacuolar H+-ATPase.
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transport of phosphate across the apical membrane of PT
cells is mediated by two sodium-coupled transporters of the
SLC34 family located in the brush border. The type 2a
sodium-phosphate co-transporter NaPi-IIa (encoded by
SLC34A1 or NPT2a) is responsible for the bulk of phosphate
reabsorption, whereas its homologue NaPi-IIc (encoded by
SLC34A, or NPT2c) is thought to play a minor role (at least
in mouse).19 As the Slc34a1-null mice show renal phosphate
wasting and hypercalciuria,20 SLC34A1 was considered as a
candidate gene for hereditary hypophosphatemic rickets with
hypercalciuria. A first study of 20 patients with persistent
hypophosphatemia due to phosphaturia, complicated with
urolithiasis or bone demineralization, identified two hetero-
zygous missense mutations in SLC34A1 in two patients.
Functional studies in Xenopus laevis oocytes suggested that
the mutant NaPi-IIa had a decreased affinity for phosphate
and defective membrane expression, with a dominant-
negative effect causing the disorder.21 It must be pointed,
however, that the functional defect associated with these
SLC34A1 variants has not been confirmed by additional
analyses.19 A recent study in a cohort of 98 pedigrees with
hypercalciuric stone-formers showed no difference in serum
and urinary phosphate levels or urinary calcium levels
between carriers and non-carriers of SLC34A1 polymorph-
isms, of which three were non-synonymous variants. The
phosphate transport activity of these mutants was either
normal or with minor kinetic changes and lower expression
levels than the wild type.22 Thus, the potential role of
SLC34A1 (NaPi-IIa) variants in hereditary hypophosphate-
mic rickets with hypercalciuria or, more generally, in renal
phosphate wasting with nephrolithiasis remains to be
confirmed.
Recently, homozygous and compound heterozygous
mutations in SLC34A3 encoding NaPi-IIc have been
identified in consanguineous kindreds and additional
families with hereditary hypophosphatemic rickets with
hypercalciuria.23 Furthermore, individuals of the affected
kindreds who were heterozygous for a SLC34A3 mutation
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Figure 1 | Schematic model linking defective endocytosis in the PT and nephrolithiasis in Dent’s disease. Albumin and low-molecular-
weight proteins, including PTH and DBP with 25(OH)D3, are filtered into the primary urine and endocytosed by PT cells via the megalin-cubilin
receptor pathway. Following internalization in coated vesicles (a), the receptor-ligand complexes progress along the endocytic pathway. The
endosomes undergo a progressive, ATP-dependent acidification that results in the dissociation of the receptor–ligand complexes, with megalin
and cubilin being recycled in the apical membrane, whereas the ligand is directed to lysosomes for degradation. In the case of 25(OH)D3-DBP,
DBP is degraded in lysosomes, whereas 25(OH)D3 is released in the cytosol and metabolized to active 1,25(OH)2D3 in mitochondria before
being released into the circulation. Vesicular acidification (b) is mediated by the vacuolar Hþ -ATPase, which requires a net Cl conductance to
dissipate the positive charge gradient. ClC-5 and other members of the CLC family are probably involved in that Cl conductance. ClC-5
functions as an electrogenic nCl/Hþ exchanger, which is predicted to facilitate acidification (at the expense of more energy) and to play a role
in keeping high vesicular Cl concentration. The functional loss of ClC-5 (c) in patients with Dent’s disease and ClC-5-null mice is reflected by
multiple trafficking defects in PT cells, with (i) loss of megalin and cubilin in the apical brush border and their accumulation in sub-apical
vesicles; (ii) defective apical endocytosis and low-molecular-weight proteinuria; and (iii) impaired progression toward lysosomes. These
modifications result in generalized dysfunction of PT cells and renal Fanconi syndrome. As DBP carries most of the circulating vitamin D in the
plasma, its urinary loss may lead to bone defects, and loss of 25(OH)D3 substrate. The increased amount of bioactive PTH in the PT lumen may
interact with apical PTH receptors and stimulate internalization and degradation of the apical NaPi-IIa co-transporter, leading to phosphaturia.
In turn, the phosphate loss could stimulate the 1a-hydroxylase activity in PT cells, leading to increased 1,25(OH)2D3 synthesis depending on
substrate availability. The balance between these effects may result in phenotype variations observed in man and mouse (see text).
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frequently showed hypercalciuria.23 These data suggest that
NaPi-IIc, which was initially considered less important than
NaPi-IIa for renal phosphate reabsorption, could play an
important role in the human kidney.19
Autosomal-dominant hypocalcemia
The G protein-coupled, extracellular calcium-sensing recep-
tor (CaSR) is a key regulator of PTH secretion and renal
tubular calcium reabsorption in response to blood calcium
levels.24 The CaSR is expressed on the apical membrane of
the PT cells and principal cells of the medullary CD and on
the basolateral membrane of cells lining the TAL and distal
convoluted tubule (DCT).24 Gain-of-function mutations in
the CASR gene that encodes the CaSR lead to autosomal-
dominant hypocalcemia, a disorder characterized by low
serum PTH levels with hypocalcemia and hypercalciuria
(reflecting decreased reabsorption of calcium in the TAL and
DCT), and in which vitamin D treatment is associated with
nephrocalcinosis and lithiasis.25 A potent gain-of-function
mutation of the CaSR (L125P) has been associated with a
salt-losing tubulopathy resulting in a secondary aldosteron-
ism, inappropriate kaliuresis, and hypokalemia, associated
with hypercalciuria and nephrolithiasis.26 These manifesta-
tions are probably explained by the inhibition of the apical
renal outer medullary potassium channel ROMK, secondary
to the constitutive activation of the mutated CaSR, leading to
decreased paracellular calcium reabsorption in the TAL. The
defect has been qualified as ‘Bartter-like syndrome type V’, in
reference with other disorders affecting NaCl transport, and
indirectly calcium reabsorption, in that segment. In parti-
cular, antenatal Bartter’s syndromes type I (mutations in
SLC12A1 coding for the Naþ -Kþ -2Cl co-transporter
NKCC2) and II (mutations in KCNJ1 coding for the Kþ
channel ROMK) are associated with fasting hypercalciuria
and nephrocalcinosis, whereas the classical Bartter’s syn-
drome type III (mutations in CLCNKB, coding for the Cl
channel ClC-Kb) is associated with variable calciuria
(Table 1). Studies looking for an association between
polymorphisms in the CASR gene and hypercalciuria among
stone-former patients yielded discrepant results,4 and the role
for CaSR in idiopathic hypercalciuria remains to be
established.
Familial hypomagnesemia with hypercalciuria and
nephrolithiasis
Claudin-16 (or paracellin-1) is a renal tight junction protein
that is expressed in the TAL, where it plays a role in the
paracellular reabsorption of magnesium and calcium.27 Over
20 loss-of-function mutations in the CLDN16 gene that
encodes claudin-16 have been identified in kindreds with
familial hypomagnesemia with hypercalciuria and nephro-
calcinosis. Familial hypomagnesemia with hypercalciuria and
nephrocalcinosis is an autosomal-recessive tubular disorder
characterized by progressive magnesium and calcium wast-
ing, leading to nephrocalcinosis and nephrolithiasis (with
incomplete distal renal tubular acidosis (dRTA) and hypoci-
traturia), and generally complicated by chronic renal failure
in early childhood or adolescence.28 These mutations can
interfere with the intracellular trafficking of claudin-16, or its
paracellular magnesium permeability.29 Interestingly, in 11 of
23 families with familial hypomagnesemia with hypercalciuria
and nephrocalcinosis due to a mutation in CLDN16, there
was at least one heterozygous individual with either
hypercalciuria or nephrolithiasis, which led to suggest that
heterozygosity for CLDN16 mutation could account for
hypercalciuria and nephrolithiasis.28 It should be noted,
however, that most patients with nephrolithiasis in that
cohort had no hypercalciuria and that the prevalence of
nephrolithiasis (9/55 patients, B16%) or hypercalciuria
(7/55, B13%) among heterozygotes was similar to the
general population.
These studies highlighted the importance of claudin-16/
paracellin-1 for the paracellular transport of magnesium and
calcium and, more generally, the functional role of tight
junction proteins. Mutations of CLDN16 are responsible for
familial hypomagnesemia with hypercalciuria and nephro-
calcinosis, but the potential role for CLDN16 heterozygous
mutations in idiopathic hypercalciuria remains unclear.
Hereditary distal renal tubular acidosis
Primary dRTA is caused by the failure of the CD to acidify
urine appropriately in the presence of systemic metabolic
acidosis and otherwise normal renal function. The cellular
basis of dRTA is a dysfunction of the a-type intercalated cells,
which mediate the secretion of protons into the urine via the
apical, multisubunit proton ATPase that is functionally
coupled to the basolateral anion exchanger AE1.30 Mutations
in three genes involved in the a-type intercalated cells have
been associated with the autosomal dominant (SLC4A1,
coding for AE1) or recessive (ATP6V1B1 and ATP6V0A4,
coding for the B1 and a4 subunits of the proton pump,
respectively) forms of dRTA (Table 1). The biochemical
manifestations of dRTA include hyperchloremic metabolic
acidosis and hypokalemia, with inappropriate alkaline urine
pH. Clinical manifestations are variable, including growth
defects, osteomalacia, and rickets, and are usually milder in
the autosomal dominant than in the recessive forms of the
disease. The latter are also causing sensorineural hearing loss
in some patients. Primary dRTA is frequently complicated by
nephrocalcinosis and/or nephrolithiasis, attributed to the
combination of hypercalciuria, hypocitraturia (due to
upregulated citrate reabsorption in the PT), and alkaline
urine. A recent biopsy study showed that stone-forming
patients with dRTA have a more diffuse papillary renal
disease than common idiopathic calcium oxalate stone
formers. The main abnormalities were plugging of inner
medullary CD profiles with calcium phosphate deposits in
the form of apatite crystals, and epithelial cell injury
surrounded by interstitial fibrosis.31 Interestingly, most of
the radiographic calcifications in these patients were
surgically removable stones rather than nephrocalcinosis
itself.31
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Thus far, none of the genes responsible for dRTA has been
associated with common idiopathic hypercalciuria or idio-
pathic calcium nephrolithiasis.4 We should mention here that
sequence variations in the SAC gene segregate with an
autosomal dominant form of absorptive hypercalciuria
(HCA2) in some kindreds.32 Interestingly, SAC encodes a
bicarbonate-activated, soluble adenylyl cyclase that is
expressed in the kidney and other acid-secreting epithelia
where it could play a role of pH sensor, mediating
bicarbonate-activated cyclic adenosine 30,50 monophosphate
signalling and vacuolar Hþ -ATPase recycling important for
luminal acidification.33
RODENT MODELS: QUANTITATIVE TRAIT LOCUS MAPPING
AND GENE TARGETING
The genetic hypercalciuric stone-forming rat model
The most studied animal model of polygenic hypercalciuria is
the GHS rat model developed by Bushinsky et al.34 The GHS
rat model was produced by selective inbreeding of hypercal-
ciuric ‘normal’ Sprague–Dawley rats over 60 generations.
Urine calcium excretion in these rats exceeds that of the
parental strain by 10-fold, and all of them develop kidney
stones. In agreement with a polygenic model, the pathophy-
siology of hypercalciuria in the GHS rat includes increased
intestinal calcium absorption; increased bone reabsorption;
and decreased renal tubular calcium reabsorption. Serum
levels of calcium are normal, but there are excessive levels of
the vitamin D receptor in all target tissues and of the CaSR in
kidney. Breeding experiments allowed to identify several
quantitative trait loci associated with hypercalciuria in this
model. In particular, a calcium excretion quantitative trait
loci (hypercalciuria 1, HC1) was identified on chromosome 1
and further isolated in a normocalciuric Wistar–Kyoto
background by developing congenic strains.35 Microarray
analysis of the gene expression patterns in the hypercalciuric
congenic strains revealed a bias in expression change for
genes located in the HC1 quantitative trait loci region.
Furthermore, a significant number of genes with altered
expression patterns are involved in calcium metabolism at
large.35 Further studies of the polygenic GHS rat model will
combine fine mapping and expression profiling, in order to
identify candidate genes contributing to hypercalciuria.
Trpv5 KO mice
The epithelial calcium channel TRPV5 is the rate-limiting
step for active, transcellular calcium reabsorption in the DCT
and CT of the kidney. TRPV5 is a member of the transient
receptor potential (TRP) channel family, which includes 28
ion channels that function as cellular sensors and regulate
various cell functions.36 Hoenderop et al.37 generated a Trpv5
KO mouse characterized by diminished active calcium
reabsorption in the DCT despite enhanced 1,25(OH)2D3
levels, with compensatory hyperabsorption of dietary cal-
cium, severe hypercalciuria, and significant bone abnormal-
ities. Despite robust hypercalciuria, mice lacking TRPV5
showed no kidney stones, but a significant polyuria. It has
been suggested that hypercalciuria activates the apical CaSR
in the principal cells of the CD, which results in the
inhibition of aquaporin-2 (AQP2)-mediated water reabsorp-
tion, diluting the luminal calcium and reducing the risk of
calcium precipitation.37 No human mutations of TRPV5
(locus 7q35) have been identified thus far and the importance
of this gene in idiopathic hypercalciuria is unknown. It must
be noted, however, that the TRPV5-mediated calcium
transport could be regulated by other molecules in the
DCT, including the serine/threonine kinase WNK4.38 Muta-
tions of WNK4, the gene that encodes WNK4, cause
autosomal dominant pseudo-hypoaldosteronism type II
(MIM 601844), characterized by hyperkalemic hypertension
associated with hypercalciuria. These features were repro-
duced in transgenic mice bearing a pseudo-hypoaldostero-
nism type II mutant Wnk4 allele, and it was demonstrated
that they are caused by an increased activity of the sodium-
chloride co-transporter NCC in the DCT.39 These findings
reveal that a tight interaction between transporters and their
regulators is important for calcium reabsorption in the DCT
and that inherited differences in the activity of these
molecules could influence calcium handling in the distal
nephron.
Caveolin-1 KO mice
Caveolin-1 is the major structural component of caveolae,
small invaginations of the plasma membrane that are
present in most cell types and play an important role in
endocytosis, transcytosis, and signal transduction.40 Caveo-
lin-1 is predominantly distributed in the basolateral area of
DCT cells in the mouse kidney.41 Of interest, male caveolin-1
KO mice showed hypercalciuria and a higher risk for calcium
stones in the urinary bladder, whereas no changes were
observed in females. These changes were associated with an
aberrant distribution of the basolateral plasma membrane
calcium ATPase in DCT cells.41 Although the reason for the
exclusive bladder stone presentation in this strain remains
unclear, these studies pointed at caveolin-1 as a potential
determinant of the renal handling of calcium – at least
in males.
CONCLUSION AND PERSPECTIVES
Our understanding of the pathophysiology of hypercalciuria
and nephrolithiasis has been improved by the identification
of rare monogenic disorders affecting distinct tubular
segments of the kidney, and the development and character-
ization of mouse models. A case in point is Dent’s disease, in
which the functional loss of a chloride transporter leads to
the unexpected combination of defective PT endocytosis with
hypercalciuria and nephrolithiasis. The deciphering of
monogenic diseases yielded candidate genes for association
studies with idiopathic hypercalciuria or calcium nephro-
lithiasis. The results of such association studies are thus far
disappointing, reflecting methodological or statistical pro-
blems as well as limitations of the hypothesis-driven
candidate gene selection for complex traits.
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Taking into account the different organs and the multiple
factors contributing to nephrolithiasis remains essential to
get new candidate genes – as illustrated in the following
examples. The majority of calcium stones are composed of
calcium oxalate. Oxalate transport is mediated by the
chloride-oxalate exchanger SLC26A6 expressed in the apical
membrane of epithelial cells in the kidney and intestine. Jiang
et al.42 generated Slc26a6-null mice, which developed a high
incidence of calcium oxalate kidney stones and hyperoxaluria.
The latter was due to increased plasma oxalate concentration,
secondary to a primary defect in intestinal oxalate secretion.
This study demonstrated the important role of SLC26A6 in
limiting the net intestinal absorption of oxalate, as an
oxalate-free diet greatly reduced the urinary and plasma
oxalate concentrations in this model. Another example is
provided by the inactivation of Umod in mouse.43 The
UMOD gene encodes uromodulin (Tamm–Horsfall protein),
the most abundant protein in the normal urine. Uromodulin
is a glycosylphosphatidylinositol (GPI) anchor-linked protein
that is synthesized in the cells lining the TAL, where it is
released into the urine by proteolytic cleavage.44 A sizeable
fraction (B15%) of the Umod KO mice showed spontaneous
formation of calcium oxalate crystals located in the
medullary CDs, whereas such crystals were never found in
wild-type littermates.43 The development of crystals was
triggered by exposure of KO mice to high calcium/high
oxalate conditions. These results demonstrated that uromo-
dulin is a protective factor against nephrolithiasis, which
could be due to its affinity to bind calcium (via calcium-
binding domains and negatively charged sialylated residues)
and a capacity to inhibit calcium crystal formation in vivo.
A deficiency in uromodulin maturation or function could
thus contribute to nephrolithiasis in man. Yet, two genes that
may potentially interfere with the maturation of uromodulin
(DPM2 and DOLPP1) are located within a new locus for
autosomal-dominant nephrolithiasis (NPL1) that was iden-
tified by a genome-wide search in a Spanish kindred.45
The quest for genes involved in hypercalciuria and
nephrolithiasis will undoubtly take advantage of high-
throughput technologies, such as genome-wide association
studies performed in selected kindreds or populations;45
microarray-based expression studies performed in relevant
animal models such as the GHS rat (see above);35 and large-
scale random mutagenesis approaches (such as the N-ethyl-
N-nitrosourea (ENU) or the isopropyl methane sulfonate
programs) in which gene discovery is driven by phenotype
analysis rather than by hypothesis. The latter approach
proved effective in generating mutants relevant for complex
human diseases including ectopic tissue calcifications.46
ACKNOWLEDGMENTS
We apologize for the many original studies that could not be
referenced because of space constraints. The authors’ investigations
were supported in part by the Fonds National de la Recherche
Scientifique, the Fonds de la Recherche Scientifique Me´dicale, the
IAP VI, an Action de Recherche Concerte´e (ARC 05/10-328), and the
EuReGene integrated project (FP6).
REFERENCES
1. Taylor EN, Curhan GC. Diet and fluid prescription in stone disease. Kidney
Int 2006; 70: 835–839.
2. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115:
2598–2608.
3. Moe OW, Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005; 16:
729–745.
4. Gambaro G, Vezzoli G, Casari G et al. Genetics of hypercalciuria and
calcium nephrolithiasis: from the rare monogenic to the common
polygenic forms. Am J Kidney Dis 2004; 44: 963–986.
5. Hunter DJ, de Lange M, Snieder H et al. Genetic contribution to renal
function and electrolyte balance: a twin study. Clin Sci 2002; 103:
259–265.
6. Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and
dietary influences on nephrolithiasis: a report from the Vietnam Era Twin
(VET) Registry. Kidney Int 2005; 67: 1053–1061.
7. Loredo-Osti JC, Roslin NM, Tessier J et al. Segregation of urine calcium
excretion in families ascertained for nephrolithiasis: evidence for a major
gene. Kidney Int 2005; 68: 966–971.
8. Lloyd SE, Pearce SH, Fisher SE et al. A common molecular basis for three
inherited kidney stone diseases. Nature 1996; 379: 445–449.
9. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes
and chloride channel mutations. Kidney Int 1998; 53: 3–17.
10. Jentsch TJ, Poet M, Fuhrmann JC, Zdebik AA. Physiological functions of
CLC Cl channels gleaned from human genetic disease and mouse
models. Annu Rev Physiol 2005; 67: 779–807.
11. Devuyst O, Christie PT, Courtoy PJ et al. Intra-renal and subcellular
distribution of the human chloride channel CLC-5, reveals a
pathophysiological basis for Dent’s disease. Hum Mol Genet 1999; 8:
247–257.
12. Hoopes Jr RR, Shrimpton AE, Knohl SJ et al. Dent Disease with mutations
in OCRL1. Am J Hum Genet 2005; 76: 260–267.
13. Piwon N, Gunther W, Schwake M et al. ClC-5 Cl-channel disruption
impairs endocytosis in a mouse model for Dent’s disease. Nature 2000;
408: 369–373.
14. Wang SS, Devuyst O, Courtoy PJ et al. Mice lacking renal chloride channel,
ClC-5, are a model for Dent’s disease, a nephrolithiasis disorder
associated with defective receptor-mediated endocytosis. Hum Mol Genet
2000; 9: 2937–2945.
15. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic
receptors. Nat Rev Mol Cell Biol 2002; 3: 256–266.
16. Jentsch TJ. Chloride and the endosomal–lysosomal pathway: emerging
roles of CLC chloride transporters. J Physiol 2007; 578: 633–640.
17. Christensen EI, Devuyst O, Dom G et al. Loss of chloride channel
ClC-5 impairs endocytosis by defective trafficking of megalin and
cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 2003; 100:
8472–8477.
18. Tieder M, Modai D, Samuel R et al. Hereditary hypophosphatemic rickets
with hypercalciuria. N Engl J Med 1985; 312: 611–617.
19. Forster IC, Hernando N, Biber J, Murer H. Proximal tubular handling of
phosphate: a molecular perspective. Kidney Int 2006; 70: 1548–1559.
20. Beck L, Karaplis AC, Amizuka N et al. Targeted inactivation of Npt2 in mice
leads to severe renal phosphate wasting, hypercalciuria, and skeletal
abnormalities. Proc natl Acad Sci USA 1998; 95: 5372–5377.
21. Prie D, Huart V, Bakouh N et al. Nephrolithiasis and osteoporosis
associated with hypophosphatemia caused by mutations in the type 2a
sodium-phosphate cotransporter. N Engl J Med 2002; 347: 983–991.
22. Lapointe JY, Tessier J, Paquette Y et al. NPT2a gene variation in
calcium nephrolithiasis with renal phosphate leak. Kidney Int 2006; 69:
2261–2267.
23. Bergwitz C, Roslin NM, Tieder M et al. SLC34A3 mutations in patients with
hereditary hypophosphatemic rickets with hypercalciuria predict a key
role for the sodium-phosphate cotransporter NaPi-IIc in maintaining
phosphate homeostasis. Am J Hum Genet 2006; 78: 179–192.
24. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular
calcium signaling. Physiol Rev 2001; 81: 239–297.
25. Pearce SH, Williamson C, Kifor O et al. A familial syndrome of
hypocalcemia with hypercalciuria due to mutations in the calcium-
sensing receptor. N Engl J Med 1996; 335: 1115–1122.
26. Vargas-Poussou R, Huang C, Hulin P et al. Functional characterization of a
calcium-sensing receptor mutation in severe autosomal dominant
hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 2002; 13:
2259–2266.
27. Simon DB, Lu Y, Choate KA et al. Paracellin-1, a renal tight junction
protein required for paracellular Mg2+ resorption. Science 1999; 285:
103–106.
Kidney International (2007) 72, 1065–1072 1071
O Devuyst and Y Pirson: Genetics of hypercalciuric nephrolithiasis m i n i r e v i e w
28. Weber S, Schneider L, Peters M et al. Novel paracellin-1 mutations in 25
families with familial hypomagnesemia with hypercalciuria and
nephrocalcinosis. J Am Soc Nephrol 2001; 12: 1872–1881.
29. Kausalya PJ, Amasheh S, Gunzel D et al. Disease-associated mutations
affect intracellular traffic and paracellular Mg2+ transport function of
Claudin-16. J Clin Invest 2006; 116: 878–891.
30. Karet FE. Inherited distal renal tubular acidosis. J Am Soc Nephrol 2002;
13: 2178–2184.
31. Evan AP, Lingeman J, Coe F et al. Renal histopathology of stone-forming
patients with distal renal tubular acidosis. Kidney Int 2007; 71: 795–801.
32. Reed BY, Gitomer WL, Heller HJ et al. Identification and characterization
of a gene with base substitutions associated with the absorptive
hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol
Metab 2002; 87: 1476–1485.
33. Pastor-Soler N, Beaulieu V, Litvin TN et al. Bicarbonate-regulated adenylyl
cyclase (sAC) is a sensor that regulates pH-dependent V-ATPase recycling.
J Biol Chem 2003; 278: 49523–49529.
34. Bushinsky DA, Frick KK, Nehrke K. Genetic hypercalciuric stone-forming
rats. Curr Opin Nephrol Hypertens 2006; 15: 403–418.
35. Hoopes Jr RR, Middleton FA, Sen S et al. Isolation and confirmation of a
calcium excretion quantitative trait locus on chromosome 1 in genetic
hypercalciuric stone-forming congenic rats. J Am Soc Nephrol 2006; 17:
1292–1304.
36. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential
cation channels in disease. Physiol Rev 2007; 87: 165–217.
37. Hoenderop JG, van Leeuwen JP, van der Eerden BC et al. Renal Ca2+
wasting, hyperabsorption, and reduced bone thickness in mice lacking
TRPV5. J Clin Invest 2003; 112: 1906–1914.
38. Jiang Y, Ferguson WB, Peng JB. WNK4 enhances TRPV5-mediated calcium
transport: potential role in hypercalciuria of familial hyperkalemic
hypertension caused by gene mutation of WNK4. Am J Physiol Renal
Physiol 2007; 292: F545–F554.
39. Lalioti MD, Zhang J, Volkman HM et al. Wnk4 controls blood pressure and
potassium homeostasis via regulation of mass and activity of the distal
convoluted tubule. Nat Genet 2006; 38: 1124–1132.
40. Williams TM, Lisanti MP. The caveolin genes: from cell biology to
medicine. Ann Med 2004; 36: 584–595.
41. Cao G, Yang G, Timme TL et al. Disruption of the caveolin-1 gene impairs
renal calcium reabsorption and leads to hypercalciuria and urolithiasis.
Am J Pathol 2003; 162: 1241–1248.
42. Jiang Z, Asplin JR, Evan AP et al. Calcium oxalate urolithiasis in
mice lacking anion transporter Slc26a6. Nat Genet 2006; 38:
474–478.
43. Mo L, Huang HY, Zhu XH et al. Tamm-Horsfall protein is a critical renal
defense factor protecting against calcium oxalate crystal formation.
Kidney Int 2004; 66: 1159–1166.
44. Devuyst O, Dahan K, Pirson Y. Tamm–Horsfall protein or uromodulin : new
ideas about an old molecule. Nephrol Dial Transplant 2005; 20:
1290–1294.
45. Wolf MTF, Zalewski I, Claverie Martin F et al. Mapping a new suggestive
gene locus for autosomal dominant nephrolithiasis to chromosome
9q33.2–q34.2 by total genome search for linkage. Nephrol Dial Transplant
2005; 20: 909–914.
46. Hough TA, Bogani D, Cheeseman MT et al. Activating calcium-sensing
receptor mutation in the mouse is associated with cataracts and ectopic
calcification. Proc Natl Acad Sci USA 2004; 101: 13566–13571.
1072 Kidney International (2007) 72, 1065–1072
m i n i r e v i e w O Devuyst and Y Pirson: Genetics of hypercalciuric nephrolithiasis
